Biolabs Strengthens Leadership: Dr. Hilton Officially Authorised by the FCA

A New Chapter of Strategic Oversight

BioLabs is pleased to announce a significant milestone in our corporate governance journey. We are proud to confirm that Dr. Paul Hilton has been officially authorised by the Financial Conduct Authority (FCA) to undertake the SMF29 Limited Scope Function for Solaris Biolabs Ltd. Effective as of 24 July 2026, this regulatory approval underscores our unwavering commitment to transparency, operational excellence, and the highest standards of corporate governance within the UK research-peptide and vertical-farming sectors.

Commitment to Regulatory Excellence

The FCA authorisation process is rigorous, requiring individuals to demonstrate the highest levels of competence and integrity. By securing this authorisation, Dr. Hilton reinforces the leadership foundation of Solaris Biolabs, ensuring that our corporate structure aligns with the robust regulatory expectations of the UK financial landscape. This development is a pivotal step in our ongoing efforts to institutionalise our operations as we continue to push the boundaries of scientific research and sustainable agriculture.

Supporting Future Growth

At BioLabs Peptides, we remain dedicated to our core mission of pioneering advancements in peptide research and vertical-farming technology. The strategic oversight provided by Dr. Hilton’s newly authorised role will prove instrumental as we scale our operations and continue to deliver high-quality, research-grade solutions to our partners. Having a leadership team that operates under the clear, mandated frameworks of the FCA allows us to focus with greater confidence on our long-term goals: accelerating innovation, ensuring product integrity, and maintaining the trust of our valued stakeholders.

Looking Ahead

This authorisation represents more than just a regulatory formality; it is a clear indicator of the maturity and professionalism that define our organisation. As we move into the second half of 2026 and beyond, we are better positioned than ever to leverage our technical expertise and our strengthened leadership structure to drive transformative change in the life sciences and agricultural industries. We remain focused on the future, prepared to explore new horizons in research and cultivation with the highest levels of oversight and dedication.